Navigation Links
Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A
Date:11/19/2010

Inspiration Biopharmaceuticals is dedicated exclusively to developing treatments for hemophilia, with a primary mission to broaden access to care, including prophylactic therapy, and to improve the treatment of individuals with inhibitor complications.  Inspiration has a broad portfolio of recombinant hemophilia products, which includes two late-stage products in clinical development and two pre-clinical programs.

Inspiration's lead product candidates are IB1001, an intravenous recombinant factor IX (FIX) for the acute and preventative treatment of bleeding in individuals with hemophilia B, and OBI-1, an intravenous recombinant porcine factor VIII (FVIII) for the treatment of individuals who have developed inhibitors against human FVIII and for individuals with acquired hemophilia A.  Both products are in clinical development.  Earlier-stage preclinical programs at Inspiration are focused on human recombinant factor VIIa (FVIIa), for individuals with either hemophilia A or hemophilia B who have developed inhibitors, and for individuals with factor VII deficiency; and human recombinant FVIII, to treat individuals with hemophilia A.

Inspiration has extensive expertise and experience in hemophilia product development, biologics manufacturing, regulatory approval and global commercialization. The Company's senior leadership was directly responsible for the development and commercialization of the majority of hemophilia products currently on the market.  In addition, in January 2010, Inspiration entered into a strategic partnership with Ipsen SA, leveraging the combined expertise and resources of the two companies.  For further information on Inspiration, please visit http://www.inspirationbio.com.


'/>"/>
SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
2. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
3. Inspiration for My Sisters Keeper Speaks Out
4. National Expressions of Courage Art Contest Unveils Stories of Inspiration
5. Inspiration Biopharmaceuticals OBI-1 Receives Orphan Drug Designation in Europe
6. Inspiration Biopharmaceuticals Awarded Two Grants Under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP)
7. Siemens MAMMOMAT Inspiration Digital Mammography Commercially Available in U.S.
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
11. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly ... property developed and owned by Hadassah University Hospital, ... center, today announced that its portfolio company, Cell ... Israeli Ministry of Industry and Commerce, Office of ... and advance clinical trials. Cell Cure,s development budget ...
(Date:5/23/2013)... May 23, 2013  Texas, premier physician associations today ... the survival tools they need to provide demonstrably better ... health care marketplace. "I am confident the ... practices," said Stephen L. Brotherton , ... Texas doctors are determined to make ...
(Date:5/23/2013)... , May 23, 2013  Net Medical Xpress ... telemedicine market, announced today the company has signed a ... staffing company based in Huntsville, AL ... specializes in the staffing and recruitment of telemedicine physicians. ... of the final agreement, which is expected by June ...
Breaking Medicine Technology:Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2TMA Launches Physician Services Organization for Patient Care 2TMA Launches Physician Services Organization for Patient Care 3TMA Launches Physician Services Organization for Patient Care 4Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 2Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 3
... state,are invited to help advance research in women,s ... The registry, created by the Institute,for Women,s Health ... developed to encourage researchers to focus on women,s ... the chance to be part of,university-sponsored research studies ...
... 13 Raven,biotechnologies, inc., a privately held company ... therapeutics (MAbs) for cancer,today announced that it has ... lead,clinical product, in combination with gemcitabine in the ... Phase 2 Pancreatic Cancer Study will be conducted ...
Cached Medicine Technology:Women Invited to Join New Health Registry to Advance Research 2Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer 2Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer 3
(Date:5/24/2013)... (PRWEB) May 24, 2013 The ... of products used outside the central laboratory, by ... a healthcare practitioner or by consumers. This includes ... fertility and pregnancy, infectious and cardiovascular disease and ... such as critical care, surgical and emergency departments. ...
(Date:5/24/2013)... of its kind, Impacts World 2013 from May ... from politics, business and civil society to discuss ... research across sectors and scales. , Webcast of ... May 27th, 1pm to 1:55pm and opening plenary ... include: , Connie Hedegaard, EU Commissioner for ...
(Date:5/24/2013)... research presented today shows that formation of new neurons ... its importance in learning and remembering - could cause ... existing brain circuits. Drs. Paul Frankland and Sheena ... Toronto, argue this reorganization could have the positive effect ... capacity for new learning. These results were presented ...
(Date:5/24/2013)... The creative flair and design talent ... (PolyU)'s Institute of Textiles and Clothing (ITC) have won ... Show held on 22 May at The Mira Hong ... ITC design students, various knitwear producers and yarn suppliers, ... of four outfits from 20 graduating students majoring in ...
(Date:5/24/2013)... -- Nearly three out of four pregnant women ... but these issues don,t significantly affect their quality ... from Loyola University Medical Center in Maywood, Ill., ... physiological and hormonal changes that occur during pregnancy. ... can play a role. The study authors added ...
Breaking Medicine News(10 mins):Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 2Health News:Point of Care Diagnostics Market (POC) Analysis and 5 Year Forecast in New Research Report at ReportsnReports.com 3Health News:New neuron formation could increase capacity for new learning, at the expense of old memories 2Health News:PolyU Stages Knitwear Fashion Show 2Health News:Bowel Issues Affect 3 Out of 4 Pregnant Women 2
... MSA ), the,global leader in the development, manufacture and ... announced today that it,will broadcast a third quarter 2007 ... 1, 2007 at 10:00 a.m. EDT. The call will,last ... have the opportunity to listen to,the conference call live ...
... therapies drugs developed to attack specific molecules in ... work well by themselves, increasingly researchers are finding that ... conventional therapies. , Reported today at the AACR-NCI-EORTC ... applications of new and existing drugs are offering new ...
... Pocket Expenses ... for Medical Foods, NOVATO, ... today that it has,provided a $250,000 grant to the National Organization ... patients with,phenylketonuria (PKU), a rare genetic metabolic disorder. Funds from this,new ...
... (OTC Bulletin,Board: NTRZ), a health science company and ... research and technology whose products include,food supplements and ... animals announced today that it has retained the ... an expanded,communications program among the investment community. ...
... have discovered a way to use a simple blood ... which gives little warning and is almost always fatal ... Public Library of Science (PLoS), represents the collaborative work ... Diagnostics. , TAAs occur in the part of the ...
... MADISON, N.J., Oct. 24 Quest Diagnostics,Incorporated (NYSE: ... diagnostic,testing, information and services, announced that for the ... operations was $150,million, or $0.77 per diluted share, ... in the third quarter of 2006. The third ...
Cached Medicine News:Health News:MSA Schedules Third Quarter Earnings Webcast 2Health News:Combination targets: some drugs may work best when they work together 2Health News:Combination targets: some drugs may work best when they work together 3Health News:Combination targets: some drugs may work best when they work together 4Health News:Combination targets: some drugs may work best when they work together 5Health News:Combination targets: some drugs may work best when they work together 6Health News:Combination targets: some drugs may work best when they work together 7Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 2Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 3Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 4Health News:BioMarin Provides Grant to NORD to Expand PKU Patient Support Services 5Health News:NutraCea Appoints Financial Relations Board as New Investor Relations Firm 2Health News:NutraCea Appoints Financial Relations Board as New Investor Relations Firm 3Health News:A new key to detecting deadly aortic aneurysms 2Health News:Quest Diagnostics Reports Third Quarter Results 2Health News:Quest Diagnostics Reports Third Quarter Results 3Health News:Quest Diagnostics Reports Third Quarter Results 4Health News:Quest Diagnostics Reports Third Quarter Results 5Health News:Quest Diagnostics Reports Third Quarter Results 6Health News:Quest Diagnostics Reports Third Quarter Results 7Health News:Quest Diagnostics Reports Third Quarter Results 8Health News:Quest Diagnostics Reports Third Quarter Results 9Health News:Quest Diagnostics Reports Third Quarter Results 10Health News:Quest Diagnostics Reports Third Quarter Results 11Health News:Quest Diagnostics Reports Third Quarter Results 12Health News:Quest Diagnostics Reports Third Quarter Results 13Health News:Quest Diagnostics Reports Third Quarter Results 14Health News:Quest Diagnostics Reports Third Quarter Results 15
... the sounds you need to ... other body sounds while reducing ... Littmann Model 3000., ,With Ambient ... to 18 times amplification, and ...
CVC 123 is an assayed quality control material used for confirming the calibration and linearity of blood gas, electrolyte, and metabolite instrumentation....
... control material used for monitoring the performance of ... for specific use on Bayer analyzers that measure ... 270) and the AVOX Systems CO-Oximeters (4000 and ... the IRMA TRUpoint. CC 527 is available in ...
Equinox is a truly unique approach to cosmetic enhancement contact lenses and is worn as a conventional wear lens....
Medicine Products: